Aurobindo Pharma announced that its wholly-owned subsidiary's unit in Andhra Pradesh received a satisfactory Voluntary Action Indicated (VAI) classification from the USFDA, following an inspection in ...

Aurobindo Pharma's Andhra plant receives USFDA's VAI classification, indicating found issues without recommended regulatory action.

Aurobindo Pharma Limited has announced that the United States drug regulator has classified Unit-IV of its wholly owned ...

Hyderabad: Aurobindo Pharma Limited on February 27, 2026 announced the completion of a US FDA inspection at Unit I of its wholly owned subsidiary Eugia Pharma Specialities Ltd. The inspection, ...

Aurobindo Pharma Limited on February 27, 2026 announced the completion of a United States inspection at its subsidiary's ...

Aurobindo Pharma has repeatedly defended its key moving average supports, as it refused to trade below the 50-day and 20-day ...

Indian drugmaker Aurobindo Pharma plans to scale up production of Penicillin-G to more than 10,000 metric tonnes annually within the next 12 months. The Hyderabad-based pharmaceutical company ...

Aurobindo Pharma’s subsidiary Eugia Pharma Unit-I in Telangana was inspected by the US FDA from February 16 to 27, 2026, ...

Hyderabad: Aurobindo Pharma has expanded its oncology portfolio in the United States through the launch of a generic version of Pomalidomide capsules by its subsidiary Eugia Pharma Specialities ...

Axis Securities said that CG Power decisively surpassed the 'multiple resistance' zone of Rs 680 on February 2026 on a ...

This initiative is part of Aurobindo Pharma’s broader strategy to strengthen its presence in international markets, particularly in the pharmaceutical sector. HYDERABAD, India — Aurobindo Pharma ...

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.